Blueprint exec spots key Ayvakit readout, dealmaking plan as 'independent precision therapy company'
Blueprint Medicines has been a possible buyout target for large pharma companies thanks to its attractive precision cancer therapy focus. But some of the Massachusetts biotech’s recent moves suggest ...
With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion. The Massachusetts biotech unveiled the new ...
(RTTNews) - Blueprint Medicines Corp. (BPMC) announced Wednesday positive top-line results from PIONEER trial of AYVAKIT (avapritinib) in patients with non-advanced systemic mastocytosis or SM. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results